{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:59:47Z","timestamp":1790827187882,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10549-016-3828-6","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T11:24:54Z","timestamp":1462965894000},"page":"307-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases"],"prefix":"10.1007","volume":"157","author":[{"given":"William","family":"Jacot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvire","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Etienne","family":"Heudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"D\u2019Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Darlix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Firmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Romieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thezenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,11]]},"reference":[{"key":"3828_CR1","author":"V Askoxylakis","year":"2016","unstructured":"Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda DG, Huang P, Fukumura D, Engelman JA, Jain RK (2016) Preclinical efficacy of ado-trastuzumab emtansine in the brain microenvironment. J Natl Cancer Inst. doi: 10.1093\/jnci\/djv313","journal-title":"J Natl Cancer Inst"},{"key":"3828_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero JM, Labbe-Devilliers C (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64\u201371. doi: 10.1016\/S1470-2045(12)70432-1","journal-title":"Lancet Oncol"},{"key":"3828_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-013-1257-5","volume":"116","author":"R Bartsch","year":"2014","unstructured":"Bartsch R, Berghoff AS, Preusser M (2014) Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 116:205\u2013206. doi: 10.1007\/s11060-013-1257-5","journal-title":"J Neurooncol"},{"key":"3828_CR4","author":"R Bartsch","year":"2015","unstructured":"Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M (2015) Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis. doi: 10.1007\/s10585-015-9740-3","journal-title":"Clin Exp Metastasis"},{"key":"3828_CR5","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972\u20132977","journal-title":"Cancer"},{"key":"3828_CR6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/bjc.2011.597","volume":"106","author":"A Berghoff","year":"2012","unstructured":"Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106:440\u2013446. doi: 10.1038\/bjc.2011.597","journal-title":"Br J Cancer"},{"key":"3828_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/0973-1482.19768","volume":"2","author":"G Biswas","year":"2006","unstructured":"Biswas G, Bhagwat R, Khurana R, Menon H, Prasad N, Parikh PM (2006) Brain metastasis\u2014evidence based management. J Cancer Res Ther 2:5\u201313","journal-title":"J Cancer Res Ther"},{"key":"3828_CR8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P","volume":"69","author":"W Boogerd","year":"1992","unstructured":"Boogerd W, Dalesio O, Bais EM, van der Sande JJ (1992) Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69:972\u2013980","journal-title":"Cancer"},{"key":"3828_CR9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2407-13-70","volume":"13","author":"AL Braccini","year":"2013","unstructured":"Braccini AL, Azria D, Thezenas S, Romieu G, Ferreri JM, Jacot W (2013) Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases. BMC Cancer 13:70. doi: 10.1186\/1471-2407-13-70","journal-title":"BMC Cancer"},{"key":"3828_CR10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.breast.2013.05.011","volume":"22","author":"AL Braccini","year":"2013","unstructured":"Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W (2013) Prognostic factors of brain metastases from breast cancer: impact of targeted therapies. Breast 22:993\u2013998. doi: 10.1016\/j.breast.2013.05.011","journal-title":"Breast"},{"key":"3828_CR11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/neuonc\/not329","volume":"16","author":"JA Carlson","year":"2014","unstructured":"Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P (2014) Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro-oncology 16:1006\u20131009. doi: 10.1093\/neuonc\/not329","journal-title":"Neuro-oncology"},{"key":"3828_CR12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6601970","volume":"91","author":"AJ Clayton","year":"2004","unstructured":"Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639\u2013643","journal-title":"Br J Cancer"},{"key":"3828_CR13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11060-015-2045-1","volume":"127","author":"CL Vries de","year":"2016","unstructured":"de Vries CL, Linn SC, Brandsma D (2016) Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. J Neurooncol 127:401\u2013403. doi: 10.1007\/s11060-015-2045-1","journal-title":"J Neurooncol"},{"key":"3828_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.2011-0212","volume":"17","author":"R Duchnowska","year":"2012","unstructured":"Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arlukowicz B, Wysocki P, Jankowski T, Radecka B, Foszczynska-Kloda M, Litwiniuk M, Debska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J (2012) Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+\u00a0advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist 17:26\u201335. doi: 10.1634\/theoncologist.2011-0212","journal-title":"Oncologist"},{"key":"3828_CR15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#","volume":"85","author":"V Franciosi","year":"1999","unstructured":"Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S (1999) Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85:1599\u20131605","journal-title":"Cancer"},{"key":"3828_CR16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745\u2013751","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3828_CR17","doi-asserted-by":"crossref","unstructured":"Hutter A, Schwetye KE, Bierhals AJ, McKinstry RC (2003) Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am 13:237\u2013250, x\u2013xi","DOI":"10.1016\/S1052-5149(03)00016-9"},{"key":"3828_CR18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10147-012-0444-2","volume":"18","author":"H Iwata","year":"2013","unstructured":"Iwata H, Narabayashi M, Ito Y, Saji S, Fujiwara Y, Usami S, Katsura K, Sasaki Y (2013) A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int J Clin Oncol 18:621\u2013628. doi: 10.1007\/s10147-012-0444-2","journal-title":"Int J Clin Oncol"},{"key":"3828_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1471-2407-10-257","volume":"10","author":"W Jacot","year":"2010","unstructured":"Jacot W, Gerlotto-Borne MC, Thezenas S, Pouderoux S, Poujol S, About M, Romieu G (2010) Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer 10:257. doi: 10.1186\/1471-2407-10-257","journal-title":"BMC Cancer"},{"key":"3828_CR20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"3828_CR21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12282-013-0513-z","volume":"22","author":"MA Kaplan","year":"2015","unstructured":"Kaplan MA, Ertugrul H, Firat U, Kucukoner M, Inal A, Urakci Z, Pekkolay Z, Isikdogan A (2015) Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab. Breast Cancer 22:503\u2013509. doi: 10.1007\/s12282-013-0513-z","journal-title":"Breast Cancer"},{"key":"3828_CR22","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1200\/JCO.2005.05.249","volume":"23","author":"DG Kirsch","year":"2005","unstructured":"Kirsch DG, Ledezma CJ, Mathews CS, Bhan AK, Ancukiewicz M, Hochberg FH, Loeffler JS (2005) Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 23:2114\u20132116. doi: 10.1200\/JCO.2005.05.249 author reply 2116\u20132117","journal-title":"J Clin Oncol"},{"key":"3828_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","volume":"26","author":"IE Krop","year":"2015","unstructured":"Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Dieras V (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26:113\u2013119. doi: 10.1093\/annonc\/mdu486","journal-title":"Ann Oncol"},{"key":"3828_CR24","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","volume":"22","author":"NU Lin","year":"2004","unstructured":"Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608\u20133617","journal-title":"J Clin Oncol"},{"key":"3828_CR25","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993\u20131999","journal-title":"J Clin Oncol"},{"key":"3828_CR26","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","volume":"15","author":"NU Lin","year":"2009","unstructured":"Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452\u20131459","journal-title":"Clin Cancer Res"},{"key":"3828_CR27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","volume":"105","author":"NU Lin","year":"2011","unstructured":"Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105:613\u2013620. doi: 10.1007\/s11060-011-0629-y","journal-title":"J Neurooncol"},{"key":"3828_CR28","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY, Response Assessment in Neuro-Oncology g (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16:e270\u2013e278. doi: 10.1016\/S1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"key":"3828_CR29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/neuonc\/nou141","volume":"17","author":"A Morikawa","year":"2015","unstructured":"Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD (2015) Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-oncology 17:289\u2013295. doi: 10.1093\/neuonc\/nou141","journal-title":"Neuro-oncology"},{"key":"3828_CR30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-007-9469-1","volume":"86","author":"K Ogawa","year":"2008","unstructured":"Ogawa K, Yoshii Y, Nishimaki T, Tamaki N, Miyaguni T, Tsuchida Y, Kamada Y, Toita T, Kakinohana Y, Tamaki W, Iraha S, Adachi G, Hyodo A, Murayama S (2008) Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 86:231\u2013238","journal-title":"J Neurooncol"},{"key":"3828_CR31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10147-008-0797-8","volume":"14","author":"M Ono","year":"2009","unstructured":"Ono M, Ando M, Yunokawa M, Nakano E, Yonemori K, Matsumoto K, Kouno T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y (2009) Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 14:48\u201352. doi: 10.1007\/s10147-008-0797-8","journal-title":"Int J Clin Oncol"},{"key":"3828_CR32","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","volume":"280","author":"RA Patchell","year":"1998","unstructured":"Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485\u20131489","journal-title":"JAMA"},{"key":"3828_CR33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12094-006-0095-8","volume":"8","author":"J Puente Vazquez","year":"2006","unstructured":"Puente Vazquez J, Lopez-Tarruella Cobo S, Garcia-Saenz JA, Casado Herraez A, Moreno Anton F, Sampedro Gimeno T, Bueno Muino C, Grande Pulido E, Martin Jimenez M, Diaz-Rubio E (2006) Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin Transl Oncol 8:50\u201353","journal-title":"Clin Transl Oncol"},{"key":"3828_CR34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W","volume":"58","author":"D Rosner","year":"1986","unstructured":"Rosner D, Nemoto T, Lane WW (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58:832\u2013839","journal-title":"Cancer"},{"key":"3828_CR35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-015-0103-5","volume":"5","author":"A Saleem","year":"2015","unstructured":"Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L, Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC (2015) Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI Res 5:30. doi: 10.1186\/s13550-015-0103-5","journal-title":"EJNMMI Res"},{"key":"3828_CR36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"HJ Stemmler","year":"2007","unstructured":"Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18:23\u201328. doi: 10.1097\/01.cad.0000236313.50833.ee","journal-title":"Anticancer Drugs"},{"key":"3828_CR37","first-page":"2474","volume":"42","author":"DJ Stewart","year":"1982","unstructured":"Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS (1982) Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42:2474\u20132479","journal-title":"Cancer Res"},{"key":"3828_CR38","author":"S Torres","year":"2014","unstructured":"Torres S, Maralani P, Verma S (2014) Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Reports. doi: 10.1136\/bcr-2014-205680","journal-title":"BMJ Case Reports"},{"key":"3828_CR39","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, Group ES (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783\u20131791. doi: 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"3828_CR40","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9440(10)61180-7","volume":"167","author":"RJ Weil","year":"2005","unstructured":"Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913\u2013920. doi: 10.1016\/S0002-9440(10)61180-7","journal-title":"Am J Pathol"},{"key":"3828_CR41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/02841860500486630","volume":"45","author":"T Yau","year":"2006","unstructured":"Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O\u2019Brien ME, Smith IE (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196\u2013201. doi: 10.1080\/02841860500486630","journal-title":"Acta Oncol"},{"key":"3828_CR42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0021-9681(60)90137-5","volume":"11","author":"C Zubrod","year":"1960","unstructured":"Zubrod C, Schneiderman M, Frei EJ (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard an triethylene thiophosphoramide. J Chron Dis 11:7\u201333","journal-title":"J Chron Dis"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3828-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3828-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3828-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T14:31:05Z","timestamp":1567866665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3828-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,11]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3828"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3828-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,11]]}}}